Ensysce Biosciences Inc(ENSC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 30 at 7:30 PM ET (Korea 10/1 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.76 | Insider Own | 4.72% | Shs Outstand | 19.5M | Perf Week | 0.31% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 94.5% | Insider Trans | - | Shs Float | 18.5M | Perf Month | 5.88% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.19 | Inst Own | 4.65% | Short Float | 6.5% | Perf Quarter | 37.82% |
| Income | -0.01B | P/S | 1.8 | EPS this Y | 72.61% | Inst Trans | 3.78% | Short Ratio | 0.08 | Perf Half Y | -22.79% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -295.93% | Short Interest | 1.21M | Perf YTD | -54.8% |
| Book/sh | -0.05 | P/C | 11.89 | EPS past 3/5Y | 87.61% - | ROE | -968.33% | 52W High | -84.88% ($2.75) | Perf Year | -82.46% |
| Cash/sh | 0.03 | P/FCF | - | Sales past 3/5Y | 26.16% 5.21% | ROIC | - | 52W Low | 80.78% ($0.23) | Perf 3Y | -97.99% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 27.41% | Gross Margin | - | Volatility(W/M) | 6.47% 8.89% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | 1.62 | Sales Y/Y TTM | -39.29% | Oper. Margin | -281.32% | ATR (14) | 0.04 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.6 | EPS Q/Q | 74.95% | Profit Margin | -280.48% | RSI (14) | 48.83 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.6 | Sales Q/Q | -15.1% | SMA20 | -6.47% ($0.45) | Beta | 1.02 | Target Price | $8.25 |
| Payout | - | Debt/Eq | - | Earnings | 2026/08/19 | SMA50 | 5.48% ($0.4) | Rel Volume | 0.02 | Prev Close | $0.42 |
| Employees | 10 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -16.33% ($0.5) | Avg Volume(3M) | 14.20M | Price | $0.42 |
| IPO | 2018/2/26 | Option/Short | No/Yes | Trades | 316 | Volume | 348,444 | Change | -0.29% |
💊 This is a clinical-stage pharmaceutical company developing next-generation painkillers with abuse-deterrent technology. It is researching new drug candidates designed to lower the abuse risk of opioids such as oxycodone, using its trypsin-activated TAAP platform and its overdose-prevention MPAR platform. The company has no commercialized products yet and remains a very small biotech that relies on its clinical-stage pipeline.
Over the past 1 year, on the lower side
85% below its 1-year high.
Traded less than usual That is 2% of its average volume.
ENSC has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +72.6% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $180. Peers typically go for $1,284.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +78% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 4.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #526 of 592 in the industry
Based on market cap of $8M.
AZTR#524 Azitra Inc $8M PER - 
KALA#525 Kala Bio Inc $8M PER - ENSC#526 Ensysce Biosciences Inc $8M PER - 
SNGX#527 Soligenix Inc $8M PER - 
CURX#528 Curanex Pharmaceuticals Inc $8M PER - 
FAQ
What kind of company is ENSC?
ENSC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ENSC?
The market cap of ENSC is approximately $8M, ranking 5,548 within its sector.
What is the 52-week high and low for ENSC?
ENSC has recorded a 52-week high of $2.75 and a low of $0.23.
